Holen Sie sich die Stockscreener-App
52.52
0.85%
-0.45
Handel nachbörslich:
52.52
Schlusskurs vom Vortag:
$52.97
Offen:
$52.59
24-Stunden-Volumen:
835.04K
Relative Volume:
0.41
Marktkapitalisierung:
$5.52B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-0.72%
1M Leistung:
+47.24%
6M Leistung:
+188.89%
1J Leistung:
+0.00%
1-Tages-Spanne:
$52.40
$53.23
1-Wochen-Bereich:
$52.09
$53.23
52-Wochen-Spanne:
$12.30
$54.47
Metsera Inc Stock (MTSR) Company Profile
Firmenname
Metsera Inc
Sektor
Branche
Telefon
(212) 784-6595
Adresse
3 WORLD TRADE CENTER, NEW YORK
Vergleichen Sie MTSR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
52.52 | 5.58B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Metsera Inc Stock (MTSR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-09-09 | Eingeleitet | Leerink Partners | Outperform |
| 2025-06-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-02-25 | Eingeleitet | BofA Securities | Buy |
| 2025-02-25 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Metsera Inc Aktie (MTSR) Neueste Nachrichten
What Fibonacci levels say about Metsera Inc. reboundJuly 2025 Catalysts & Daily Risk Controlled Trade Plans - newser.com
What machine learning models say about Metsera Inc.Market Volume Summary & Fast Exit/Entry Strategy Plans - newser.com
How Metsera Inc. stock reacts to Fed rate cutsWeekly Stock Summary & Consistent Growth Equity Picks - newser.com
IP Group: Metsera deal highlights hidden value, say analysts - Proactive financial news
IP Group shares fly on back of Metsera & Pfizer news - BusinessCloud
IP Group notes potential income from Metsera obesity drugs - MarketScreener
IP Group shares climb 9% on potential royalties from Pfizer’s $7.3bn Metsera deal - Proactive Investors
IP Group Poised for Potential Royalty Windfall from Metsera’s Obesity Drug Pipeline - AskTraders.com
IP Group eyes potential royalties from obesity drug - The Armchair Trader
IP Group eyes future royalties from obesity drug candidates following Pfizer/Metsera deal - Proactive financial news
IP Group’s Edge in Obesity Drugs: Pfizer-Metsera Deal Insight - Kalkine Media
IP Group Sees Revenue Potential From Metsera Obesity Drug Deal - DirectorsTalk Interviews
IP Group Anticipates Revenue Boost from Metsera’s Obesity Drug Development - TipRanks
Real time alert setup for Metsera Inc. performancePortfolio Gains Summary & Growth Focused Entry Point Reports - newser.com
Metsera (MTSR): Evaluating Valuation After a 48% One-Month Share Price Surge - Yahoo Finance
Metsera (NASDAQ:MTSR) Receives Sell (D) Rating from Weiss Ratings - MarketBeat
Metsera Inc. stock trend forecastJuly 2025 Action & Smart Allocation Stock Tips - newser.com
How to integrate Metsera Inc. into portfolio analysis toolsQuarterly Profit Summary & AI Enhanced Trading Signals - newser.com
Pfizer Aims To Close Gap On Obesity Drugs With Metsera 09/23/2025 - MediaPost
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates UNP, MTSR, SCS on Behalf of Shareholders - The Malaysian Reserve
Novo Nordisk’s liver deal misses bigger ailment - Reuters
What data driven models say about Metsera Inc.’s futureJuly 2025 Weekly Recap & Trade Opportunity Analysis - newser.com
Does Metsera Inc. show high probability of reboundSwing Trade & Accurate Intraday Trading Signals - newser.com
Is Metsera Inc. stock near bottom after declineJuly 2025 Market Mood & Weekly Breakout Stock Alerts - newser.com
Will Metsera Inc. rebound enough to break even2025 Market Sentiment & Consistent Income Trade Ideas - newser.com
Applying Elliott Wave Theory to Metsera Inc.Weekly Stock Analysis & Technical Pattern Based Signals - newser.com
Pfizer: Mastering The Art Of The Deal With MetseraUpgraded To Buy (NYSE:PFE) - Seeking Alpha
Pfizer to Buy Metsera for $4.9 Billion in Obesity Drug Bet - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Inside INdiana Business - FinancialContent
Down 50%, Should You Buy the Dip on Pfizer? - The Motley Fool
Is this a good reentry point in Metsera Inc.Exit Point & Consistent Return Investment Signals - newser.com
Is Metsera Inc. stock poised for growthWeekly Profit Analysis & Growth Focused Investment Plans - newser.com
Will earnings trigger a reversal in Metsera Inc.July 2025 PostEarnings & Verified Trade Idea Suggestions - newser.com
Is Metsera Inc. stock resilient to inflationJuly 2025 Highlights & Daily Stock Trend Watchlist - newser.com
Market Movers: Metsera and Apple surge, Kenvue falters on Tylenol troubles - MSN
Where Metsera’s data fit in the obesity landscape - BioCentury
Will Metsera Inc. stock split again soonWeekly Market Report & Expert Curated Trade Setup Alerts - newser.com
Metsera (NASDAQ:MTSR) Raised to "Hold" at Wall Street Zen - MarketBeat
Metsera’s Phase IIb GLP-1 Data Show Competitive Efficacy, Tolerability - insights.citeline.com
Metsera strengthens case for Pfizer buyout with latest study data - BioPharma Dive
Metsera Reports Up To 14% Weight Loss In Phase 2b Obesity Trial - inkl
PFE stock rises 5.3% today: Pfizer seals Trump drug price deal with $70 billion U.S. investment and $7.3 b - The Economic Times
PFE stock rises 5.3% today: Pfizer seals Trump drug price deal with $70 billion U.S. investment and $7.3 billion Metsera weight-loss acquisition - MSN
Finanzdaten der Metsera Inc-Aktie (MTSR)
Es liegen keine Finanzdaten für Metsera Inc (MTSR) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):